Alcon EBITDA 2011-2026 | ALC

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Alcon

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	-	580 M	-482 M	-187 M	-248 M	-77 M	1.29 B	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
1.29 B	-482 M	146 M

Quarterly EBITDA Alcon

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	229 M	-	-	-	-466 M	-	-	-	-53 M	-	-	-	38 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
229 M	-466 M	-63 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Medical instruments industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
AtriCure ATRC	2.64 M	$ 28.66	1.52 %	$ 1.37 B	USA
Atrion Corporation ATRI	37.7 K	-	-	$ 810 M	USA
Luminex Corporation LMNX	72.9 M	-	-	$ 1.75 B	USA
Akers Biosciences, Inc. AKER	-12.3 M	-	-9.52 %	$ 20.6 M	USA
Ekso Bionics Holdings EKSO	-11.8 M	$ 9.63	6.76 %	$ 23.4 M	USA
The Cooper Companies COO	1.06 B	$ 71.7	0.69 %	$ 14.3 B	USA
Antares Pharma, Inc. ATRS	16.2 M	-	-	$ 955 M	USA
Cantel Medical Corp. CMD	123 M	-	-1.18 %	$ 3.4 B	USA
CRH Medical Corporation CRHM	33.9 M	-	-	$ 282 M	USA
Hill-Rom Holdings, Inc. HRC	518 M	-	-0.05 %	$ 10.3 B	USA
Haemonetics Corporation HAE	337 M	$ 59.27	3.4 %	$ 2.98 B	USA
Varian Medical Systems, Inc. VAR	60 M	-	-0.02 %	$ 16.3 B	USA
Harvard Bioscience HBIO	-46.8 M	$ 4.66	8.0 %	$ 207 M	USA
iRhythm Technologies IRTC	-36.7 M	$ 120.45	4.52 %	$ 3.85 B	USA
electroCore ECOR	-12.7 M	$ 6.29	3.37 %	$ 53.4 K	USA
Repro Med Systems KRMD	-2.16 M	$ 4.34	3.09 %	$ 200 M	USA
Isoray ISR	-110 M	-	0.03 %	$ 108 M	USA
Glaukos Corporation GKOS	-95 M	$ 119.49	2.65 %	$ 5.79 B	USA
Masimo Corporation MASI	-164 M	$ 178.47	0.08 %	$ 9.51 B	USA
Microbot Medical MBOT	-14.7 M	$ 2.35	-9.27 %	$ 108 M	Israel
ICU Medical ICUI	244 M	$ 129.32	2.9 %	$ 3.19 B	USA
Milestone Scientific MLSS	-5.62 M	$ 0.29	3.8 %	$ 23.8 M	USA
InfuSystem Holdings INFU	15 M	$ 9.73	3.73 %	$ 201 M	USA
Merit Medical Systems MMSI	308 M	$ 70.57	3.38 %	$ 4.17 B	USA
Envista Holdings Corporation NVST	332 M	$ 26.91	1.97 %	$ 4.52 B	USA
Pro-Dex PDEX	11.9 M	$ 52.4	1.79 %	$ 172 M	USA
Intuitive Surgical ISRG	3.55 B	$ 458.96	1.85 %	$ 164 B	USA
Predictive Oncology POAI	-181 M	-	-	$ 31.1 M	USA
LeMaitre Vascular LMAT	78.3 M	$ 115.17	0.48 %	$ 2.61 B	USA
BioLife Solutions BLFS	-1.97 M	$ 20.11	1.87 %	$ 926 M	USA
Retractable Technologies RVP	-13.4 M	$ 0.7	4.31 %	$ 21 M	USA
Baxter International BAX	673 M	$ 17.63	2.8 %	$ 9.04 B	USA
ResMed RMD	1.16 B	$ 230.26	0.61 %	$ 33.6 B	USA
STERIS plc STE	1.34 B	$ 224.85	1.03 %	$ 22.2 B	USA
Pulse Biosciences PLSE	-76.5 M	$ 18.92	1.34 %	$ 1.28 B	USA
Teleflex Incorporated TFX	192 M	$ 123.18	4.05 %	$ 5.5 B	USA
Stereotaxis STXS	-21.5 M	$ 1.92	2.67 %	$ 175 M	USA
STAAR Surgical Company STAA	-83.4 M	$ 26.84	1.51 %	$ 1.33 B	USA
NeuroMetrix NURO	-8.69 M	-	5.05 %	$ 9.02 M	USA
Utah Medical Products UTMD	12.2 M	$ 67.15	1.9 %	$ 218 M	USA
DENTSPLY SIRONA XRAY	-70 M	$ 12.02	2.65 %	$ 2.4 B	USA
West Pharmaceutical Services WST	756 M	$ 259.96	1.33 %	$ 18.8 B	USA
AngioDynamics ANGO	-14.2 M	$ 10.24	4.49 %	$ 418 M	USA
Becton, Dickinson and Company BDX	5.04 B	$ 155.43	0.78 %	$ 44.7 B	USA
Nephros NEPH	-1.38 M	$ 2.91	-1.69 %	$ 30.2 M	USA
OraSure Technologies OSUR	-61.8 M	$ 3.08	4.05 %	$ 226 M	USA
Repligen Corporation RGEN	116 M	$ 122.59	2.07 %	$ 6.83 M	USA